Posted by rickygiam > 1 day ago | Report Abuse

Those who sold 4.87 good move.... Back to 4.6

Posted by stncws > 1 day ago | Report Abuse

1632 cannot BREAK, means is bear is coming, stock crash soon... now foreign fund should be exiting...best time when u happy happy

Posted by neohts > 1 day ago | Report Abuse

Well. Different person different opinions. Tomorrow will know. Game not over yet. TauRX results could be earlier.

Posted by Michaelchan2024 > 1 day ago | Report Abuse

According to Maybank IB Research, the share price weakness was more likely due to foreign selling from the weaker ringgit compared to the US dollar.

The research house added that since inflation in the United States has tapered down, and the ringgit is likely to recover against the dollar backed by the prospect of the Federal Reserve cutting the interest rate, it hopes the foreign selling will decrease.

“Our FX Research Team forecasts the US dollar/ringgit to recover to 4.600 by end-2024, and 4.500 by mid-2025 from 4.718 as at June 30, 2024.

Posted by Michaelchan2024 > 1 day ago | Report Abuse

Fed could cut rates by 25 bps in July, another 50 bps to follow in September: Moody’s.

马屁精 is right,
Don't be conned and
don't be cheated..

Posted by speakup > 1 day ago | Report Abuse

Trump is very pro-strong US Dollar. so Fed may delay rate cuts to keep dollar strong

Posted by speakup > 1 day ago | Report Abuse

Trump is very high chance become next Presiden

Posted by Michaelchan2024 > 1 day ago | Report Abuse

Times have indeed changed since Trump's first term. The interest rate environment is much higher today, and maintaining high rates indefinitely is not sustainable. The Fed may have to balance between supporting the economy and keeping the dollar "strong".

Posted by Pinky > 1 day ago | Report Abuse

Trump is also very pro-business.

Lower rates is better for business.

Posted by kl_guy > 1 day ago | Report Abuse

RSS sell off about 300k at rm4.77.

Posted by Junichiro > 1 day ago | Report Abuse

US is likely to go into recession after their election. Rate cuts are likely.

Posted by Ravetidus > 1 day ago | Report Abuse

yes a recession is coming, n that would then lead to rate cuts to help support the economy

Posted by bullrun168 > 1 day ago | Report Abuse

Walaoeh, what happend ?
Super damn hot man Genting today !
Now Genting was traded at @RM4.80 (+0.04) (+0.8 %)
Heng ah, Ong ah, Huat ah !

Posted by stncws > 1 day ago | Report Abuse

bear is coming.. 1632 cant break

Posted by stncws > 1 day ago | Report Abuse

bear is coming.. 1632 cant break

Posted by Save > 1 day ago | Report Abuse

Foreign fund nett buying Day 13 yesterday +64M, Local institution keep nett selling -84M. KLCI short term target 1630 seems broken, let see closing index if can maintain above 1630. Any successful breakout will bring KLCI towards 1680! Is Genting turn this round? Watch 4.85

Posted by bullrun168 > 1 day ago | Report Abuse

Wow, Amazing !
Now Genting was traded @RM4.81 (+0.05) (+1.1 %)
Heng ah, Ong ah, Huat ah !

Posted by AngTayKor > 1 day ago | Report Abuse

Alzheimer's biotech Asceneuron raises $100M to see if it can compete with Lilly, Biogen on tau

A small Swiss biotech has raised a $100 million Series C to start testing its oral small molecule for Alzheimer’s disease in a Phase 2 later this year.

Asceneuron, a Merck KGaA spinout, is developing the O-GlcNAcase (OGA) inhibitor ASN51 and is hoping to go up against the two leading drugmakers in the Alzheimer’s field: Eli Lilly and Biogen.

The 12-year-old biotech started raising the Series C around the beginning of the year, CEO Barbara Angehrn Pavik said in an interview. She joined last fall after helping Vifor exit to CSL for $11.7 billion as chief business officer. Asceneuron was light on specifics of the Phase 2 trial design, including whether it’d be a global study.

Led by Novo Holdings, the Series C is expected to fully fund the trial and potentially see whether ASN51 can be developed for additional conditions, including Parkinson’s and amyotrophic lateral sclerosis, according to new board member Naveed Siddiqi, a senior partner on the venture investments team at Novo Holdings.

In addition to Novo Holdings, other investors in the Series C include new backers EQT Life Sciences’ LSP Dementia Fund, OrbiMed and SR One, along with existing financial supporters M Ventures, Sofinnova Partners, GSK Equities Investments and Johnson & Johnson Innovation’s JJDC.
Race with Lilly, Biogen

Biogen and Lilly are also developing their own experimental medicines aiming to inhibit the OGA enzyme with the goal of slowing down or curbing the buildup of tau protein.

Biogen and Lilly’s current marketed drugs — Leqembi and Kisunla, respectively — go after the pesky protein amyloid. But their new medicines, alongside Asceneuron, seek to destroy tau. The neurodegenerative-linked protein comes after amyloid and can damage neurons upon accumulation.

Lilly is in the lead on the OGA front, with a Phase 2 of its drug LY3372689 estimated to wrap up this summer, according to the federal trials database. Biogen’s candidate, named BIIB113, completed a Phase 1 last year. Multiple other drugmakers are developing anti-tau treatments with different approaches.

Leqembi was approved in 2023, but has had a slow commercial rollout, and Kisunla secured FDA approval last month after multiple delays over the past year. These anti-amyloid drugs have to be infused, which can be a strain on healthcare systems and can cause logistical hurdles for patients, and they’ve come with safety concerns about brain swelling and bleeding.

“The infrastructure and cost of this is enormous, so what the field really needs is an oral, a pill, you could take at home. And what we picked up was that there is a new class coming through of OGA inhibitors, which Lilly, Biogen and Asceneuron are developing,” Siddiqi said.

“Lilly will hopefully validate this class later on this year, and then we are second after that in a very large market,” Siddiqi said. He said it’s believed that tau is “more highly correlated with the loss of your cognition than amyloid is.”

The field has been trying to tackle tau for years. Lilly, Biogen, Roche, AbbVie and others have attempted anti-tau approaches with monoclonal antibodies, but none of them panned out in key clinical studies. “If you want an efficacious tau-targeting approach or therapy, it really is going to need to influence the aggregation of tau inside the cell,” Asceneuron SVP of R&D Ryan Schubert said.
----------------------


Asceneuron's development stage now is like 19 years ago when Taurx initiated phase 2 REMBER trial using first generation MTC drug formula.

Posted by kent9988 > 1 day ago | Report Abuse

hi bro @AngTayKor
did u know the latest news of taurx with fda type c meeting?they still not yet meeting right?

Posted by AngTayKor > 1 day ago | Report Abuse

September meeting. FDA wants us to combine both AA and Full Approval sessions into 1 meeting instead of 2 separate meetings. KNN how to do both of them within a 60 min meeting? I think better focus on AA liow as Full Approval seems like a long shot to me due to trial placebo issues.

Posted by kent9988 > 1 day ago | Report Abuse

thank you...
urm...wat is AA ah?,,,hahaha

Posted by benqwe12345 > 1 day ago | Report Abuse

Looking to buy Taurx shares in the secondary market.....
Can I know roughly know the market price of Taurx per share?

Posted by AngTayKor > 1 day ago | Report Abuse

Accelerated Approval. Its usually a 8 to 10 yrs temporary commercialisation Approval to sell the drug but need to do n complete another confirmatory trial within this duration. AA primarily deals with biomarkers like Tau reduction, NfL reduction, slowdown in brain shrinkage to gain quick temporary approval. For taurx's case, although our drug can totally halt cognition decline n even reverse back up (its a cure), our placebo arm was later found to be an active dose (a low dose MTC formula for blue pee discolouration). Hence using traditional full approval standards, i doubt FDA will give us full approval (didn't meet primary endpoints measurements when compared against placebo arm)

Posted by Pinky > 1 day ago | Report Abuse

Ini kalilah recovery!

Posted by RInvest > 1 day ago | Report Abuse

TauRX will put many other similar drugs for Alzheimers out of business .. probably explains why its stuck at FDA approval ..

Posted by neohts > 23 hours ago | Report Abuse

The future is very bright.
Just hold on to your shares.

Posted by Michaelchan2024 > 20 hours ago | Report Abuse

https://www.cnbc.com/2024/07/17/global-chip-stocks-from-nvidia-to-asml-fall-as-geopolitics-trump-weigh.html
TECH
Global chip stocks from Nvidia to ASML fall on geopolitics, Trump comments

Posted by Michaelchan2024 > 20 hours ago | Report Abuse

MAGA: Trump will make the US great again. With Resorts World New York City and Resorts World Las Vegas expected to see exponential growth, Genting Berhad could be headed to the moon!

Posted by stampid54 > 20 hours ago | Report Abuse

Genting moves back up after markets digested Uncle Lim's luxurious salaries 😁

Posted by ClaraChan94 > 20 hours ago | Report Abuse

Tourism Malaysia aims for RM88bil receipts in 2024. Sound good to GENTING

https://www.thestar.com.my/metro/metro-news/2024/07/11/tourism-malaysia-aims-for-rm88bil-receipts-in-2024

Posted by ImCK > 19 hours ago | Report Abuse

https://theedgemalaysia.com/node/719242 ASEAN can invest easily to bursa

Posted by ImCK > 19 hours ago | Report Abuse

bursa a lot undervalue stock

Posted by benqwe12345 > 19 hours ago | Report Abuse

Can I know Taurx current share price?

Posted by Riaz1954 > 18 hours ago | Report Abuse

Placebo issue has a precedent where by a drug was approved without the use of placebo. So technically speaking TauRX could address the issue.

Posted by StakesAreHigh > 17 hours ago | Report Abuse

Tomorrow rally

Posted by AngTayKor > 17 hours ago | Report Abuse

@Riaz, unfortunately FDA is not our friend. The FDA officials (civil service) are usually more cozy with large pharma MNCs due to future job prospects at the private sector.

Posted by Riaz1954 > 5 hours ago | Report Abuse

@AngTayKor, I understand. Not a level playing field. Loaded with politics. They protect their own. I suspect MHRA could be 1st.

Posted by Peaches L > 4 hours ago | Report Abuse

YTLPowr already passed baton to GenB now to continue d run. Let’s enjoy d show…

Posted by MG9231 > 4 hours ago | Report Abuse

https://www.youtube.com/watch?v=fFFPrEiskjc

https://www.youtube.com/watch?v=FH3M_7W9o84&t=572s

Will recent high court decision on 4D and Sports TOTO be a catalyst for Genting?

Posted by Pinky > 4 hours ago | Report Abuse

End of AI play is near. Rotation play next! Time for laggards to take over

Posted by Riaz1954 > 22 minutes ago | Report Abuse

Indeed Genting is a big laggard. It needs a catalyst. It seems there are nobody willing to chase. When time comes like an earthquake it will catapult! Wait at the starting blocks. Anytime after Sept I say.